NEW YORK (GenomeWeb) – Human Longevity will use imaging data from CorTechs Labs for the genomic and phenotypic database Human Longevity is building, the companies announced today.
CorTechs will provide quantitative evaluations of specially acquired magnetic resonance imaging data that will be integrated with other information from Human Longevity, including results from genome and microbiome sequencing, as well as metabolomics and proteomics data "to provide the most complete description of health ever assembled," the partners said in a statement.
The database being built is a crucial part of Human Longevity's goal of better understanding diseases associated with getting older and then intervening in the process, according to the companies. Launched in March, San Diego-based Human Longevity develops diagnostics, therapeutics, and stem cell treatments for aging-related ailments by combing omics data with clinical information. Craig Venter co-founded the company and serves as its chairman and CEO.
CorTechs, also headquartered in San Diego, develops products for measuring brain atrophy in neurodegenerative diseases.
Financial and other terms of the agreement were not disclosed.
Human Longevity aims to "revolutionize healthcare [by] using the most advanced tools available for predicting, preventing, and treating disease, and imaging is a critical component for this," Venter said in a statement. "The image analysis tools CoreTechs has developed and brought to market are ideal to translate imaging data into quantifiable phenotypes that can scale to a project of this size."